Abstract: Disclosed are chimeric antigen receptors comprising a CD2 co-stimulatory domain that retain function against CD58? and CD58low tumor cells, and CD2 co-stimulatory receptors that promote CAR function against CD58? and CD58low tumor cells.

Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3 K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.

Abstract: Compositions and methods are provided for decreasing processing of chondroitin sulfate proteoglycan 4 (CSPG) in treatment of gliomas, which treatment may be combined with administration of an immune-oncology agent.

Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.

Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.

Abstract: Compositions and methods for treatment of glioma are disclosed. In particular, the invention relates to methods of treating glioma by inhibiting pleiotrophin signaling to limit high-grade glioma invasion.

Abstract: Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.

Abstract: Compositions and methods for treatment of glioma are disclosed. In particular, the invention relates to methods of treating glioma by inhibiting pleiotrophin signaling to limit high-grade glioma invasion.

Abstract: Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.